Brokerages Set ProQR Therapeutics (NASDAQ:PRQR) PT at $9.50

ProQR Therapeutics (NASDAQ:PRQR) has earned a consensus rating of “Buy” from the six ratings firms that are covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $9.50.

A number of research firms have commented on PRQR. Citigroup raised ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price objective on the stock in a research note on Monday, March 10th. HC Wainwright lifted their price target on ProQR Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, March 14th. Oppenheimer assumed coverage on shares of ProQR Therapeutics in a report on Friday, January 10th. They set an “outperform” rating and a $15.00 price objective on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Finally, Chardan Capital reissued a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a research note on Friday, March 14th.

ProQR Therapeutics Trading Down 2.1 %

NASDAQ:PRQR opened at $1.40 on Friday. The stock has a market capitalization of $147.30 million, a P/E ratio of -4.38 and a beta of 0.24. ProQR Therapeutics has a 1 year low of $1.40 and a 1 year high of $4.62. The firm has a 50 day moving average of $2.08 and a 200-day moving average of $2.59.

Hedge Funds Weigh In On ProQR Therapeutics

Several large investors have recently bought and sold shares of PRQR. Alpine Global Management LLC bought a new position in ProQR Therapeutics during the fourth quarter worth about $39,000. Woodline Partners LP acquired a new stake in shares of ProQR Therapeutics in the 4th quarter valued at approximately $9,426,000. Velan Capital Investment Management LP bought a new position in ProQR Therapeutics during the 4th quarter worth approximately $107,000. Squarepoint Ops LLC grew its holdings in ProQR Therapeutics by 16.3% during the fourth quarter. Squarepoint Ops LLC now owns 83,114 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 11,623 shares during the period. Finally, Two Sigma Investments LP increased its stake in ProQR Therapeutics by 512.8% in the fourth quarter. Two Sigma Investments LP now owns 383,134 shares of the biopharmaceutical company’s stock valued at $1,015,000 after purchasing an additional 320,614 shares in the last quarter. 32.65% of the stock is currently owned by institutional investors and hedge funds.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).